Effects of Exogenous Neurokinin B Administration on Hematological and Coagulation Parameters in Adult Male New Zealand White Rabbits
DOI:
https://doi.org/10.51846/jucmd.v3i2.3184Keywords:
Tachykinins, Neurokinin B, Platelets, Blood Coagulation, Activated Partial Thromboplastin Time, Prothrombin Time, Blood Coagulation TestsAbstract
Objective: To explore the effects of varying doses of Neurokinin B (NKB) on hematological and coagulation parameters in adult male rabbits. Methodology: This experimental study was conducted at Gomal University, Dera Ismail Khan, Pakistan from June-2019 to June-2020. Eighteen adult male New Zealand white rabbits, weighing 1.5–2 kgs each, were divided randomly in to three groups (n=6 animals/ group). Group-I rabbits (control) received injections of distilled water subcutaneously. Group-II rabbits received 1 µg NKB, Group-III rabbits received 1ηg NKB subcutaneously twice daily (12 hourly), consecutively for 12 days. Animals from each group were sacrificed after 12 days of continuous treatment and blood collected for analysis of hematological [complete blood count (CBC)] and coagulation parameters [Bleeding time (BT), clotting time (CT), prothrombin time (PT) and activated partial thromboplastin time (APTT)]; CBC was performed by automated hematology analyzer, while CT and BT by Duke’s and capillary tube methods respectively; PT and APTT were analyzed using commercially available kits as per manufacturer’s instructions.
Results: BT was significantly prolonged in NKB-treated rabbits compared to control (group-II: 367.5±28.06sec, group-III:302.5±39.59sec, control: 102.5±22.08sec). CT was also increased (group-II: 317.50±25.84sec, group-III: 280±32.40sec, control: 157.50±28.06sec),
as did PT (group-II: 37.0±3.69sec, group-III: 23.67±1.21sec, control: 22.0±1.41sec) and APTT (group-II: 39.0±2.89sec, group III 25.50±1.87sec, control: 20.83±2.32sec). Additionally, mean platelet volume [group-II: 6.57±0.30fl, group-III: 6.55±0.36fl,
control: 6.05±0.27fl] and leukocyte count (×103/µl) [group-II: 15.73±1.38, group-III: 14.88±1.56, control: 8.22±1.16] were significantly increased inNKB-treated animals. International normalized ratio was significantly increased at group-II (2.0±0.1)
compared to control (1.1±0.07). Conversely, platelet count (×103/µl) was decreased significantly in all NKB-treated animals (group-II =143.50±13.60, group-III=179.67±28.09) compared to control (246.34±28.73).
Conclusion: Neurokinin B administration led to leukocytosis, thrombocytopenia, with prolonged BT, CT, PT and APTT dose-dependently.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Faiqah Ramzan, Andaleeb Asmat, Tahira Atta, Muhammad Haris Ramzan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository, in a journal or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process.
